Caris & Co Initiates Coverage Biotechnology and Drug Stocks AMLN & ALKS
Caris & Co initiates coverage on Amylin Pharmaceuticals (Nasdaq: AMLN) with a Buy rating. PT $27. Caris also initiates coverage on Alkermes (Nasdaq: ALKS) with an Above Average rating. PT $15.
Get Alerted When News Hits On This Stock - FREE!